Page last updated: 2024-10-15

5,10,15,20-tetra(4-hydroxyphenyl)porphyrin

Description

5,10,15,20-tetra(4-hydroxyphenyl)porphyrin: structure in first source; tumor localizer; do not confuse with THPP [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135438030
CHEMBL ID507897
SCHEMBL ID499290
MeSH IDM0145884

Synonyms (36)

Synonym
tpp(4-oh)4
tetra-(4-hydroxyphenyl)-porphyrin
4-[(5z,10z,14z,19z)-10,15,20-tris(4-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol
dd-011
5,10,15,20-tetrakis(4-hydroxyphenyl)-21h,23h-porphine, dye content 95 %
para-tetrahydroxyphenylporphyrin
CHEMBL507897
T1497
5,10,15,20-tetrakis(4-hydroxyphenyl)-21h,23h-porphine
5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin
51094-17-8
AKOS004904159
para-thpp
4-hydroxyphenylporphyrin
tetra(p-hydroxyphenyl)porphyrin
phenol, 4,4',4'',4'''-(21h,23h-porphine-5,10,15,20-tetrayl)tetrakis-
5,10,15,20-tetra(4-hydroxyphenyl)porphyrin
4-hydroxyphenyl-porphyrin
5,10,15,20-tetrakis-(4-hydroxyphenyl)-21h,23h-porphyrin
4,4',4'',4'''-(21h,23h-porphine-5,10,15,20-tetrayl)tetrakis-phenol
5,10,15,20-tetrakis-(4-hydroxy-phenyl)-porphyrin
5,10,15.20-tetrakis-(4-hydroxy-phenyl)-porphyrin
VFHDWGAEEDVVPD-UHFFFAOYSA-N
SCHEMBL499290
mfcd00191501
4-[7,12,17-tris(4-hydroxyphenyl)-21,22,23,24-tetraazapentacyclo[16.2.1.1?,?.1?,??.1??,??]tetracosa-1,3,5,7,9,11(23),12,14,16,18(21),19-undecaen-2-yl]phenol
tetra-(4-hydroxyphenyl)porphin
BS-16931
YSWG511
4,4,4,4-(21h,23h-porphine-5,10,15,20-tetrayl)tetrakis-phenol
A50788
4-[10,15,20-tris(4-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol
A923948
SY052953
CS-0085712
HY-W035140

Dosage Studied

ExcerptReference
"In targeted photodynamic therapy (tPDT), photosensitizers (PS) are targeted to disease tissue to reduce the dosage of PS and in addition to reduce the photo damage to the non-target tissue."( Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles.
Irudayaraj, J; Manorama, SV; Narsireddy, A; Rao, NM; Vijayashree, K, 2014
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID421020Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells assessed as reduction of infectious viral titer at 100 nM incubated for 1 hr under laminar flow hood light before infection measured after 3 days2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID390653Phototoxicity against mouse 4T1 cells on exposure to 3.8 J/cm'2 light after 16 hrs by Trypan blue exclusion method2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Glycol porphyrin derivatives as potent photodynamic inducers of apoptosis in tumor cells.
AID386643Phototoxicity against human HL60 cells on exposure to 3.8 J/cm'2 light after 16 hrs by Trypan blue exclusion method2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Glycol porphyrin derivatives as potent photodynamic inducers of apoptosis in tumor cells.
AID1845447Photocytotoxicity against human WiDr cells assessed as lethal dose incubated for 18 hrs followed by replacement of medium containing compound with 48 hrs incubation and subsequent light irradiation of 13.5 mW/cm2 at 435 nm measured after 48 hrs by MTT ass2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer.
AID421021Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells assessed as reduction of infectious viral titer at 500 nM incubated for 1 hr under laminar flow hood light before infection measured after 3 days2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.45)18.7374
1990's3 (9.68)18.2507
2000's7 (22.58)29.6817
2010's15 (48.39)24.3611
2020's4 (12.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]